Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Amortization of Deferred Charges (2021 - 2025)

Historic Amortization of Deferred Charges for P3 Health Partners (PIIIW) over the last 4 years, with Q3 2025 value amounting to $19.4 million.

  • P3 Health Partners' Amortization of Deferred Charges rose 5689.46% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 3829.77%. This contributed to the annual value of $87000.0 for FY2024, which is 8156.78% down from last year.
  • As of Q3 2025, P3 Health Partners' Amortization of Deferred Charges stood at $19.4 million, which was up 5689.46% from $71000.0 recorded in Q2 2025.
  • In the past 5 years, P3 Health Partners' Amortization of Deferred Charges registered a high of $19.4 million during Q3 2025, and its lowest value of -$12.2 million during Q4 2024.
  • In the last 4 years, P3 Health Partners' Amortization of Deferred Charges had a median value of $171936.0 in 2021 and averaged $1.5 million.
  • The largest annual percentage gain for P3 Health Partners' Amortization of Deferred Charges in the last 5 years was 1893384.62% (2024), contrasted with its biggest fall of 1830000.0% (2024).
  • Quarter analysis of 4 years shows P3 Health Partners' Amortization of Deferred Charges stood at $1.3 million in 2021, then crashed by 94.73% to $67000.0 in 2023, then tumbled by 18300.0% to -$12.2 million in 2024, then skyrocketed by 259.18% to $19.4 million in 2025.
  • Its Amortization of Deferred Charges stands at $19.4 million for Q3 2025, versus $71000.0 for Q2 2025 and $331000.0 for Q1 2025.